On May 18, 2021, GlaxoSmithKline and Medicago reported positive interim Phase 2 clinical trial safety and immunogenicity data for Medicagoﾒs plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSKﾒs pandemic adjuvant.

The Phase 3 trial of the vaccine candidate launched on 16 Mar. 2021. Trial sites are currently enrolling subjects in Canada, the U.S., the UUK and Brazil, with additional sites expected to be added.